{"transactions":[{"id":951492,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:23:25.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001380762-26-000002","document":"form4-01052026_090119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076226000002/form4-01052026_090119.xml","form_type":"4"}},{"id":998891,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":false,"shares":21828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":21828},"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":998890,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":21828,"price":8.7067,"value":190049.8476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":10789,"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":998889,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":true,"shares":21828,"price":0.64,"value":13969.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025."}],"balance_after":32617,"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":1314779,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:44.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":261900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":261900,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":261900},"source":{"system":"sec-edgar","filing":"0001415889-25-000462","document":"form4-01032025_040128.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000462/form4-01032025_040128.xml","form_type":"4"}},{"id":1332329,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-12","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":21828,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1332328,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":46828,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1332327,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-12","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":12.2973,"value":307432.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction report was $12.2973, and the range of prices were between $12.13 and $12.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":6024,"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1332326,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-12","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":0.64,"value":16000.0,"ownership":{"direct":true},"balance_after":31024,"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1332325,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":12.4284,"value":186426.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction report was $12.4284, and the range of prices were between $12.34 and $12.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":6024,"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1332324,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-12-14T00:52:26.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":0.64,"value":9600.0,"ownership":{"direct":true},"balance_after":21024,"source":{"system":"sec-edgar","filing":"0001415889-24-029376","document":"form4-12142024_121223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029376/form4-12142024_121223.xml","form_type":"4"}},{"id":1426546,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-21T22:51:45.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":61828,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-24-021886","document":"form4-08212024_100842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021886/form4-08212024_100842.xml","form_type":"4"}},{"id":1426545,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:51:45.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":15,"value":750000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023."}],"balance_after":6024,"source":{"system":"sec-edgar","filing":"0001415889-24-021886","document":"form4-08212024_100842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021886/form4-08212024_100842.xml","form_type":"4"}},{"id":1426544,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:51:45.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":0.64,"value":32000.0,"ownership":{"direct":true},"balance_after":56024,"source":{"system":"sec-edgar","filing":"0001415889-24-021886","document":"form4-08212024_100842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021886/form4-08212024_100842.xml","form_type":"4"}},{"id":1432537,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-15T20:30:12.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":111828,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-24-021364","document":"form4-08152024_040809.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021364/form4-08152024_040809.xml","form_type":"4"}},{"id":1432536,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-15T20:30:12.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":13,"value":390000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023."}],"balance_after":6024,"source":{"system":"sec-edgar","filing":"0001415889-24-021364","document":"form4-08152024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021364/form4-08152024_040809.xml","form_type":"4"}},{"id":1432535,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-08-15T20:30:12.000Z","date":"2024-08-13","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":0.64,"value":19200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,159 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") on June 30, 2023, 1,013 shares acquired under the ESPP on December 29, 2023 and 2,852 shares acquired under the ESPP on June 29, 2024."}],"balance_after":36024,"source":{"system":"sec-edgar","filing":"0001415889-24-021364","document":"form4-08152024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021364/form4-08152024_040809.xml","form_type":"4"}},{"id":1687839,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:42:31.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":350000,"derivative":{"exercise_price":5.58,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-24-000810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919124000810/doc4.xml","form_type":"4"}},{"id":2062771,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-05T22:00:45.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":145000,"derivative":{"exercise_price":8.42,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001209191-23-001926","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123001926/doc4.xml","form_type":"4"}},{"id":3827692,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former SVP, Chief Dev Officer"}}],"security":"Common Stock","published_at":"2018-09-04T17:04:47.000Z","date":"2018-08-30","kind":"tax_withholding","acquired":false,"shares":43225,"price":0.33,"value":14264.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security."}],"balance_after":115891,"source":{"system":"sec-edgar","filing":"0001017491-18-000083","document":"wf-form4_153609507190879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749118000083/wf-form4_153609507190879.xml","form_type":"4"}},{"id":3827691,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former SVP, Chief Dev Officer"}}],"security":"Common Stock","published_at":"2018-09-04T17:04:47.000Z","date":"2018-08-30","kind":"exercise","acquired":true,"shares":81775,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units accelerated upon the Reporting Person's involuntary termination.  Restricted stock units convert into common stock on a one-for-one basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units accelerated upon the Reporting Person's involuntary termination.  Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":159116,"source":{"system":"sec-edgar","filing":"0001017491-18-000083","document":"wf-form4_153609507190879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749118000083/wf-form4_153609507190879.xml","form_type":"4"}},{"id":4113778,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-03T19:45:41.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest with respect to one-fourth of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years so the option will be fully vested as of 1/3/2022, subject to the Reporting Person's continued employment or service to the Issuer through such date."}],"balance_after":60000,"derivative":{"exercise_price":2.11,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001017491-18-000006","document":"wf-form4_151502672545044.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749118000006/wf-form4_151502672545044.xml","form_type":"4"}},{"id":4113777,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2018-01-03T19:45:41.000Z","date":"2018-01-01","kind":"tax_withholding","acquired":false,"shares":5485,"price":1.84,"value":10092.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security."}],"balance_after":159116,"source":{"system":"sec-edgar","filing":"0001017491-18-000006","document":"wf-form4_151502672545044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749118000006/wf-form4_151502672545044.xml","form_type":"4"}},{"id":4215187,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2017-09-07T16:09:17.000Z","date":"2017-09-05","kind":"tax_withholding","acquired":false,"shares":14093,"price":1.56,"value":21985.08,"ownership":{"direct":true},"balance_after":164601,"source":{"system":"sec-edgar","filing":"0001017491-17-000101","document":"wf-form4_150481494394097.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749117000101/wf-form4_150481494394097.xml","form_type":"4"}},{"id":4293758,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2017-06-05T16:10:55.000Z","date":"2017-06-01","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of 75,000 Restricted Stock Units (\"RSUs\") under the Issuer's Amended and Restated 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting in the first open trading window following the Issuer's submission of Vitaros in the United States to the Food and Drug Administration (\"FDA\") and the other half of the underlying shares vesting in the first open trading window following the Issuer's receipt of marketing approval of Vitaros in the United States by the FDA, subject to the Reporting Person's continued employment or service to the Issuer through such date and subject to accelerated vesting upon a change in control of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not Applicable."}],"balance_after":178694,"source":{"system":"sec-edgar","filing":"0001017491-17-000087","document":"wf-form4_149669343893094.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749117000087/wf-form4_149669343893094.xml","form_type":"4"}},{"id":4372869,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2017-03-24T16:13:13.000Z","date":"2017-02-15","kind":"tax_withholding","acquired":false,"shares":1495,"price":2.78,"value":4156.1,"ownership":{"direct":true},"balance_after":103694,"source":{"system":"sec-edgar","filing":"0001017491-17-000037","document":"wf-form4_149038637892946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749117000037/wf-form4_149038637892946.xml","form_type":"4"}},{"id":4496830,"issuer":{"id":93662,"kind":"organization","name":"SEELOS THERAPEUTICS, INC.","symbol":"SEEL"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Development Officer"}}],"security":"Common Stock","published_at":"2017-01-06T19:31:05.000Z","date":"2017-01-05","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Award of 75,000 Restricted Stock Units (\"RSUs\") under the Issuer's 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting in the first open trading window following the Issuer's receipt of marketing approval of Vitaros in the United States by the Food and Drug Administration and the other half of the underlying shares fully vesting on November 30, 2018, subject to the Reporting Person's continued employment or service to the Issuer through such date and subject to accelerated vesting upon a change in control of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":105189,"source":{"system":"sec-edgar","filing":"0001017491-17-000017","document":"wf-form4_148374905227468.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1017491/000101749117000017/wf-form4_148374905227468.xml","form_type":"4"}}]}